BioCentury
ARTICLE | Strategy

Doctors in the house

GSK is internalizing external innovation, bringing academics in house

November 30, 2017 9:41 PM UTC

While academic partnerships have become par for the course in pharma, GSK is going a step beyond the standard model of external alliances by bringing professors in-house with virtually unrestricted access to its activities. The initiative is the latest example of pharmas lowering their guard in order to both access cutting-edge science and foster the ecosystem’s future innovators.

It’s a necessary but worthwhile price to pay, according to Paul-Peter Tak, who created the program, dubbed Immunology Network, in 2015. Tak is Chief Immunology Officer and SVP of the R&D Pipeline at GlaxoSmithKline plc...